BMX-001

Phase 2Small molecule

BBioMimetix JV, LLC

BMX-001 is one of 78 small molecule programs targeting Endometrial Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Endometrial CancerNot yet recruiting

Rectal CancerRecruiting

Endometrial CancerPhase 2

Not yet recruiting

Rectal CancerPhase 2

Recruiting

Competition

Competitive Landscape

85 competitors in Endometrial Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

52 2

Keytruda

Merck & Co.

Phase 3

21 3

Femara

Novartis

Phase 3

17 4

Paraplatin

AAvyxa

Phase 3

37 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

28 6

Megace

Bristol-Myers Squibb

Phase 3

9 7

Lenvima

Eisai

Phase 3

6 8

Lynparza

AstraZeneca

Phase 3

6 9

Tecentriq

Roche

Phase 3

4 10

Depo-Provera

Eli Lilly

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1/2Not yet recruiting

Endometrial Cancer

NCT06620029

Q4 2029

Phase 1/2Active, not recruiting

Newly Diagnosed

NCT03386500

Q2 2034

Phase 2Recruiting

Rectal Cancer

NCT05254327

Clinical

Trials by Indication[1]

Newly Diagnosed1 trial

Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer

Active, not recruiting·UUniversity of Nebraska·Phase 1/2·NCT03386500·24 enrolled

Whole-Brain Radiotherapy1 trial

A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy

Terminated·BBioMimetix JV, LLC·Phase 1/2·NCT03608020·35 enrolled

Endometrial Cancer1 trial

BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer

Not yet recruiting·BBioMimetix JV, LLC·Phase 1/2·NCT06620029·27 enrolled

Locally Advanced Head and Neck Cancer1 trial

A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer

Completed·BBioMimetix JV, LLC·Phase 1/2·NCT02990468·29 enrolled

Glioma1 trial

Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001

Completed·BBioMimetix JV, LLC·Phase 1/2·NCT02655601·177 enrolled

2 more indications

Head and Neck Cancer1 trial

Trial of BMX-001 or Placebo in Head and Neck Cancer Patients

Withdrawn·BBioMimetix JV, LLC·Phase 2·NCT04607642

Rectal Cancer1 trial

A Randomized Phase 2 Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With and Without BMX-001 as Part of Total Neoadjuvant Therapy in Patients With Newly Diagnosed Locally Advanced Rectal Adenocarcinoma

Recruiting·UUniversity of Nebraska·Phase 2·NCT05254327·118 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for BMX-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BMX-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BMX-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioMimetix JV, LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BBioMimetix JV, LLC

BMX-001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2029

Q2 2034

Trials by Indication[1]

Newly Diagnosed1 trial

Whole-Brain Radiotherapy1 trial

Endometrial Cancer1 trial

Locally Advanced Head and Neck Cancer1 trial

Glioma1 trial

Head and Neck Cancer1 trial

Rectal Cancer1 trial

References

Drug Info

Quick Facts

Related News